These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

976 related items for PubMed ID: 22607009

  • 1. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.
    J Clin Oncol; 2008 Aug 01; 26(22):3743-8. PubMed ID: 18669461
    [Abstract] [Full Text] [Related]

  • 6. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
    Noronha V, Joshi A, Bakshi G, Tongaonkar H, Prabhash K.
    Indian J Cancer; 2016 Aug 01; 53(1):102-8. PubMed ID: 27146754
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib in kidney cancer: 10 years of experience and development.
    Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S.
    Expert Rev Anticancer Ther; 2017 Feb 01; 17(2):129-142. PubMed ID: 27967249
    [Abstract] [Full Text] [Related]

  • 8. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY, Rini B.
    Expert Opin Pharmacother; 2011 May 01; 12(7):1171-89. PubMed ID: 21470066
    [Abstract] [Full Text] [Related]

  • 9. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C, Szczylik C.
    Cancer Treat Rev; 2009 May 01; 35(3):297-307. PubMed ID: 19249157
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
    Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I.
    Cancer Sci; 2011 Nov 01; 102(11):1949-57. PubMed ID: 21812860
    [Abstract] [Full Text] [Related]

  • 11. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
    Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.
    Ann Oncol; 2015 Jun 01; 26(6):1118-1123. PubMed ID: 25701452
    [Abstract] [Full Text] [Related]

  • 12. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
    JAMA; 2006 Jun 07; 295(21):2516-24. PubMed ID: 16757724
    [Abstract] [Full Text] [Related]

  • 13. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.
    N Engl J Med; 2007 Jan 11; 356(2):115-24. PubMed ID: 17215529
    [Abstract] [Full Text] [Related]

  • 14. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM, Szczylik C, Rini B.
    Expert Rev Anticancer Ther; 2014 Sep 01; 14(9):983-99. PubMed ID: 25066545
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sunitinib.
    Heng DY, Kollmannsberger C.
    Recent Results Cancer Res; 2010 Sep 01; 184():71-82. PubMed ID: 20072832
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ, Kolesar JM.
    Am J Health Syst Pharm; 2008 Jan 15; 65(2):123-31. PubMed ID: 18192256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.